Loading clinical trials...
Loading clinical trials...
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Conditions
Interventions
seladelpar 5-10 mg
seladelpar 10 mg
+1 more
Locations
156
United States
Institute for Liver Health
Chandler, Arizona, United States
Mayo Clinic Arizona - PPDS
Phoenix, Arizona, United States
The Institute for Liver Health-Tucson
Tucson, Arizona, United States
Cedars Sinai Medical Center
Los Angeles, California, United States
Stanford University School of Medicine
Redwood City, California, United States
University of California Davis Medical Center
Sacramento, California, United States
Start Date
October 1, 2018
Primary Completion Date
February 16, 2020
Completion Date
February 16, 2020
Last Updated
August 2, 2022
NCT07304843
NCT07449793
NCT05751967
NCT05749822
NCT06755541
NCT07296458
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions